Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER
Thank you for visiting Dr. Anthony D'Amico’s Giving Page. Your gift will directly support Dr. D'Amico’s innovative research at Dana-Farber Cancer Institute, and provide an invaluable resource to the fight against cancer. Thank you for your thoughtful generosity.
Recent Advances in Research
Dr. D’Amico and his team continue to make to make advances towards his ultimate goal: an era of precision medicine in prostate cancer treatment.
· Dr. D’Amico is leading the analysis of a large international clinical trial that evaluates the efficacy of adding the chemotherapy taxotere to radiation and hormone therapy for patients with prostate cancer at high risk of becoming metastatic. Researchers followed participants for seven years post-treatment, and collected tissue samples to look for the genomic predictors of response to taxotere. This information can help physicians determine in whom taxotere is likely to be life prolonging, thereby eliminating unnecessary side effects in men who will not benefit from a particular therapy.
· Dr. D’Amico is also leading an international study evaluating the impact of adding novel hormonal therapies to treatment in men with high-risk disease whose PSA does not decline below 0.5 following the first six months of treatment with radiation and hormone therapy. It has been shown that when a PSA does not decline below this threshold there is a poor clinical outcome often leading to death from the disease. Rather than wait for PSA to start to decline in this very high-risk population, only to rise again signaling a recurrence, Dr. D’Amico and his team have designed an international clinical trial to inform the impact of early intervention on reducing recurrence and death from this disease.
· Dr. D'Amico has partnered with an international academic center in Hamburg, Germany to define management approaches of the most aggressive type of prostate cancer (Gleason score 9 or 10) that offer the highest control rates. Given that at least 80% of men with this form of prostate cancer recur and many who recur die of these disease, this project promises to increase control rates and reduce death from prostate cancer.
· Dr. D’Amico is investigating the use of multi-parametric MRIs to identify patients at early risk for recurrence before the initiation of radiation therapy and after the first two months of androgen depravation therapy. This technology is also being utilized to minimize rectal and bladder side effects while improving cancer control through more precise visualization of the prostate, rectum and bladder during the delivery of radiation therapy.
To contribute by check, please write "Dr. D'Amico’s Giving Page" in the memo line, and send to:
Giving Pages
Dana-Farber Cancer Institute
Division of Development & The Jimmy Fund
10 Brookline Place West, 6th Fl
Brookline, MA 02445
617-632-6247
THANK YOU TO OUR TEAM MEMBERS
= Team CaptainTHANK YOU TO OUR TEAM DONORS
